The bill amends the Public Health Code to create an ibogaine grant program within the Department of Health and Human Services (DHHS) to fund certified clinical drug development trials for ibogaine, which is proposed for treating opioid use disorder and other neurological or mental health conditions. The DHHS will award grants to qualified entities with a history of research in neurological diseases and the capacity to conduct clinical trials. Additionally, the bill establishes an ibogaine research fund, allocated $50 million from the Michigan opioid healing and recovery fund for the fiscal year ending September 30, 2026, to support this initiative. It also sets forth conditions for prescribing and administering ibogaine, requiring that only licensed physicians can prescribe it after FDA approval, and that it must be administered in a hospital or licensed health facility under physician supervision.

Moreover, the bill modifies the classification of various substances under controlled substances law, introducing new legal language to clarify definitions and classifications of certain synthetic drugs, including JWH-200, JWH-250, and mephedrone, while updating terminology for substances like Catha edulis and Salvia divinorum. It specifies that all parts of these plants, along with their extracts and derivatives, are included in the controlled substances list. The bill also reclassifies marihuana as a schedule 2 controlled substance if handled in compliance with the act and federal authority, while providing exemptions for ibogaine used in specific research programs and prescribed under certain conditions. This comprehensive approach aims to enhance clarity and enforceability in the regulation of both traditional and synthetic drugs.

Statutes affected:
House Introduced Bill: 333.7212